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processes of the RB1/E2F pathway. Furthermore, based on the 
comparison of our work in SCLC and the works of others in 
different cancer types, EZH2 seems to regulate various apop-
totic factors in a cancer-specific manner. This work further 
confirms the oncogenic role of EZH2 in SCLC and empha-
sizes the great opportunity and promise for the development 
of novel therapeutic agents that target EZH2 for the treatment 
of this aggressive cancer.
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Erratum
Impact of PET Staging in Limited-Stage Small-Cell Lung Cancer: Erratum
One of the articles cited by the authors in the article that appeared on page 899 of the July issue of the Journal of Thoracic Oncology was not included in the 
reference list. The study by Lee et al. cited at the end of page 899 should have appeared in the reference list as follows:
Lee JW, Lee SM, Lee HS, et al. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients 
with small cell lung cancer. Ann Nucl Med. 2012;26:627–633.
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